Immunotherapy is a method of treating cancer that uses drugs to empower the immune system to recognize and fight cancer. MSK has been a pioneer in developing immunotherapy. The approach has proven very effective in treating advanced melanoma.

Lung Cancer Immunotherapy is broadly divided into four main categories which includes Checkpoint inhibitors, Therapeutic vaccines, Monoclonal antibodies and T cell transfer. Checkpoint Inhibitors serve as checks and balances in the regulation of immune responses.

Therapeutic vaccines target tumor or shared -specific antigens. Monoclonal antibodies (mAbs) are molecules target specific antigens on tumors. In T cell transfer activity of T- cells is enhanced by modification or treatment with chemicals. They are modified with goal to improve immune system response against cancer. Immunotherapy for lung cancer, alone or in combination with conventional treatments, can significantly improve outcomes for patients fighting lung cancer. Immunotherapy doesn't usually cure advanced lung cancer, but it can give some patients more time with family and friends. For nearly five decades, doctors have used various forms of immunotherapy to treat certain cancers.

As the most common cancer worldwide, lung cancer impacts approximately 2.1 million people—and causes an estimated 1.7 million deaths—each year and is the leading cause of cancer-related deaths for both men and women. In the United States alone, there were an estimated 228,000 new lung cancer cases along with 135,000 deaths in 2020. Lung cancer claims more lives every year than do cancers of the breast, prostate, and colon combined.

Kindly submit your manuscript at https://www.longdom.org/submissions/immunotherapy-open-access.html or you can mail through this mail id as an attachments immunother@emedsci.com 

Explore more information at Immunotherapy Open Access. You can share your experiences too by publishing your novel fact findings in this Journal.

Regards

Alex John
Immunotherapy Open Access
Editorial Manager     
E-mail id: immunotherapy@scholarlymed.com